Tanner Pharma Group and Biodexa Pharmaceuticals (BDRX) have announced a strategic partnership to enable global access to eRapa for patients with Familial Adenomatous Polyposis, FAP, through an Early Access / Named Patient Program. Through this collaboration, Tanner Pharma will facilitate compliant, controlled access to eRapa in countries where it is not currently available, allowing clinicians treating FAP patients to prescribe this investigational therapy outside of a clinical trial for the first time.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BDRX:
- Biodexa Pharmaceuticals Posts 2025 Preliminary Results and Deepens GI Cancer-Focused Pipeline
- Biodexa Pharmaceuticals management to meet with Maxim
- Biodexa Pharmaceuticals Announces Reverse ADR Split to Support Nasdaq Compliance
- Biodexa Pharmaceuticals announces one-for-five reverse ADR split
- Biodexa Pharmaceuticals supports Life’s a Polyp Foundation